Logo

argenx’s Vyvdura Injection Receives MHLW’s Approval for Generalized Myasthenia Gravis

Share this
argenx

argenx’s Vyvdura Injection Receives MHLW’s Approval for Generalized Myasthenia Gravis

Shots:

  • The Japanese MHLW has granted approval to Vyvdura (efgartigimod alfa and hyaluronidase-qvfc) injection for SC use to treat generalized myasthenia gravis (gMG) patients having inadequate response to steroids or non-steroidal immunosuppressive therapies (ISTs)
  • The approval was supported by the P-III (ADAPT-SC) trial, a bridging study to the P-III (ADAPT) trial of Vyvgart, investigating the noninferiority of PD effect of Vyvdura vs Vyvgart in adult patients (n=110), randomized 1:1, with gMG
  • The study results revealed that Vyvdura reduced total immunoglobulin G (IgG) levels from baseline vs Vyvgart (IV) in adult gMG patients

Ref: argenx | Image: argenx

Related News:- Argenx Reports Results of VYVGART Hytrulo in P-III study for Primary Immune Thrombocytopenia

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions